STEAP1 (STEAP Family Member 1)

P1/2, N=177, Recruiting, AstraZeneca

Ongoing studies are exploring rational combinations with hormonal, other targeted, and immune-based therapies to enhance efficacy, overcome resistance, and expand the role of ADCs in advanced prostate cancer. Herein, we provide a comprehensive overview of the clinical development of ADCs in advanced prostate cancer.

In vivo, STEAP1 silencing effectively reduced the growth of subcutaneous tumors in nude mice. STEAP1 promotes HCC growth and metastasis by activating the Wnt/β-catenin signaling pathway, and may serve as a promising therapeutic target for HCC.

The designed vaccine construct demonstrated extensive global HLA allele coverage (97.51%), strong binding affinity to B-cell receptors, MHC molecules, and favorable structural stability during molecular dynamics simulations. These findings suggest that the proposed multi-epitope vaccine represents a promising immunotherapeutic candidate for prostate cancer and warrants further experimental validation.

P=N/A, N=675, Recruiting, Thomas Jefferson University | Trial completion date: May 2026 --> Dec 2026 | Trial primary completion date: Feb 2026 --> Jul 2026

Barrier-matched strategies include T-cell redirection (PSMA/STEAP1 engagers, bispecifics, CAR-T) and combinations that heat or modulate myeloid cells. Treating immune heterogeneity as a clinical variable enables durable immunotherapy in PCa.

Ongoing investigation into novel targets for the treatment of prostate cancer continues to identify promising antigens which are overexpressed on the cell surface. Patterns of expression may vary based on histologic type, anatomic location, and treatment state of prostate cancer, and these factors will ultimately dictate the utility of novel therapeutic agents that are in development.

This study provides preclinical evidence of antigenicity and MHC-I compatibility of four prostate cancer-derived CTL epitopes using a transgenic mouse model. These findings support the advancement of these peptides as candidates for peptide-based immunotherapy in prostate cancer.

These findings suggest that systemic inflammation induced by T-cell activation following BSTP0204A treatment may have resulted in increased STEAP1 expression, inducing additional inflammation and tissue damage. This work demonstrated the need to understand not only baseline target expression for T-cell engaging therapies, but also expression under conditions such as inflammation, injury, or disease.

P1, N=50, Active, not recruiting, Amgen | Recruiting --> Active, not recruiting | Trial completion date: Jun 2029 --> Dec 2028 | Trial primary completion date: Apr 2027 --> Oct 2026

P=N/A, N=30, Active, not recruiting, Universita di Verona

We expanded the phenotype to include cytopenia and neonatal HLH. Our report on two affected male siblings highlights the expanded phenotype, clarifies the phenotypic spectrum of STEAP3, and broadens its genetic inheritance, ultimately providing a clinical and molecular workup for neonatal patients with unexplained HLH.